Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Asymptomatic or “Silent” Atrial Fibrillation: Frequency in Untreated Patients and Patients Receiving Azimilide

Open access
Page, Richard L., Tilsch, Thomas W., Connolly, Stuart J., Schnell, Daniel J., Marcello, Stephen R., Wilkinson, William E., Pritchett, Edward L.C. · 2003 · Circulation

Abstract

Background— Asymptomatic, or “silent” atrial fibrillation could increase the risk of stroke. Little is known about the frequency of asymptomatic atrial fibrillation in patients who also have symptomatic atrial fibrillation; similarly, little is known about the effect of antiarrhythmic drug therapy on asymptomatic atrial fibrillation. Methods and Results— Patients in sinus rhythm with a history of symptomatic atrial fibrillation or atrial flutter received placebo or azimilide (35 to 125 mg) once daily for 6 or 9 months in 4 similar double-blind trials. The end point was the first recurrence of a symptomatic ECG-documented supraventricular arrhythmia. Routine transtelephonic electrocardiograms, in the absence of symptoms, were recorded for 30 seconds every 2 weeks until patients completed follow-up or documented a symptomatic supraventricular arrhythmia. Of the 1380 patients, 489 received placebo. Among these patients receiving placebo, 303 transmitted at least one routine ECG while asymptomatic. Asymptomatic atrial fibrillation was recorded in 50 (17%) within 6 months and before recurrence of symptomatic supraventricular arrhythmia. In the 3 trials evaluating azimilide in therapeutic doses (100 and 125 mg), asymptomatic atrial fibrillation occurred in 49 of 382 (13%) receiving azimilide and 43 of 233 (18%) receiving placebo. Although drug effect on time to first asymptomatic event was not statistically significant (hazard ratio, 0.70; P =0.09), there was a 40% reduction in asymptomatic atrial fibrillation on azimilide compared with placebo ( P =0.03) when repeated observations were considered. Conclusions— Asymptomatic atrial fibrillation is common in untreated patients with a history of symptomatic atrial fibrillation (and is likely underestimated by this analysis). Azimilide may reduce the occurrence of this silent arrhythmia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000051455.44919.73

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 166

Metadata

Authors
Page, R. L., Tilsch, T. W., Connolly, S. J., Schnell, D. J., Marcello, S. R., Wilkinson, W. E., & Pritchett, E. L. C.
Venue
Circulation
Published
2003-03-04
Volume
107
Issue
8
Pages
1141-1145
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2140716209
Cited by
166
References
4
FWCI
11.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Asymptomatic or “Silent” Atrial Fibrillation: Frequency in Untreated Patients and Patients Receiving Azimilide. https://app.cochat.ai/papers/10.1161/01.cir.0000051455.44919.73
The paper
Page, R. L., Tilsch, T. W., Connolly, S. J., Schnell, D. J., Marcello, S. R., Wilkinson, W. E., & Pritchett, E. L. C. (2003). Asymptomatic or “Silent” Atrial Fibrillation: Frequency in Untreated Patients and Patients Receiving Azimilide. Circulation. https://doi.org/10.1161/01.cir.0000051455.44919.73

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.